Safety of the IPERF Femoral Arterial Cannula in Patients Undergoing Planned Cardiac Surgery With Extracorporeal Circulation Via Femoral Approach

NCT07163234 · tracked via the Priya Life Science France tracker

Sponsor

IPERF SAS

Phase

Not applicable

Started

2026-02-11

Last updated

2026-02-27

Condition(s) studied

Cardiac SurgeryIschemia Limb

Investigational drug(s) / intervention(s)

Cardiac surgery

Cardiac surgery: cardiac surgery

Study summary

This is a first-in-human, prospective, single-arm, phase I clinical study evaluating the safety of the iPerf femoral arterial cannula in patients undergoing planned cardiac surgery requiring extracorporeal circulation (ECC) via a femoral approach for up to 6 hours. The iPerf device is a dual-lumen arterial cannula designed to provide systemic and lower limb perfusion during ECC, with the goal of reducing the risk of acute limb ischemia. The study will be conducted at a single center in France and will include 15 adult patients. Primary outcomes focus on procedure-related and late adverse events up to 30 days post-surgery. Secondary objectives include assessment of ischemic events, tissue oxygen saturation, and surgeon satisfaction with device handling. The study aims to demonstrate feasibility and safety of the iPerf cannula as an innovative solution for lower limb perfusion during femoral artery cannulation.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion criteria * Patient aged 18 years or older * Patient able to understand the study procedures, provide written informed consent, and comply with study procedures * Patients with planned cardiac surgery requiring the use of an extracorporeal circulation via a femoral approach for a maximum of 6 hours. * Patient affiliated to the social security system Exclusion criteria * Patient weighting less than 45 kg * Patient weighting more than 130 kg * Patient with common femoral artery diameter less or equal to 6 mm * Patient with a stenosis of the aorta, iliac artery, or femoral artery reducing their diameter of more than 50% * Patient with previous vascular or endovascular surgery of the iliac or femoral arteries * Patient participating in another interventional study * Patients with known arterial dissection * Patient who is pregnant at the time of enrollment * Patients under judicial protection, guardianship or curatorship or subjects deprived of their liberty by judicial or administrative decision

Primary outcome measure(s)

Safety of the novel IPERF femoral arterial cannula — From enrollment to 30-60 days post surgery
Per procedure and late adverse events related to the IPERF Femoral Arterial Cannula, up to 30 days after surgery.

Trial sites (2)

Facility	City	Region	Status
Hôpital privé Jacques Cartier - Ramsay Santé	Massy	France	Not Yet Recruiting
Hopital Jacques Cartier - Ramsay Santé	Massy	France	Recruiting

Other trials for the same condition

Natriuresis-guided Depletion After Cardiac Surgery Recruiting

Non-interventional Study Exploring the Composition of the Valvular Microbiota of Patients Undergoing Cardiac Surgery Recruiting

Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children Recruiting

Fluid-removal Guided by VeXUS Score With Usual Care in Patients With Acute Kidney Injury After Cardiac Surgery Recruiting

SAGE-Heart : Senior Assessment fraGility and Post-opErative QALYs 1 Year After Emergency HEART Surgery for Patients Aged 75 and Older Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07163234 on ClinicalTrials.gov ↗ ← All trials in France